Annual Recurring Revenue (ARR)HealthTechSeries B

Annual Recurring Revenue (ARR) for HealthTech at Series B

2026 data · Sample size: 476 · Source: Redpoint Free Trial Benchmarks

25th %ile

$2,143,205

Median

$3,599,161

75th %ile

$4,713,166

90th %ile

$7,577,597

▲Trending up year-over-year

About This Metric

Annualized value of recurring revenue, the primary valuation metric for SaaS companies.

MRR × 12

Higher is better · Unit: currency

How to Improve

Accelerate top‑of‑funnel growth while improving conversion rates at every stage. Focus on enterprise and mid‑market customers with higher contract values. Build a scalable GTM engine with repeatable playbooks for each segment. Drive expansion revenue through multi‑product and usage‑based pricing. Reduce logo and revenue churn to preserve the existing ARR base.

Ehsan's Analysis

HealthTech ARR benchmarks need to be evaluated on a revenue-quality basis. A healthtech company with $5M ARR from 10 hospital contracts (average $500K each, 3-year terms) has fundamentally different revenue quality than a consumer healthtech with $5M ARR from 50,000 app subscribers ($100/year each, month-to-month). The hospital contracts have 95%+ renewal probability and the consumer subscriptions have 40% annual retention. Investors increasingly use "durable ARR" — ARR weighted by contract commitment length — which gives 3-year contracts 3x the weight of month-to-month. By this measure, the B2B healthtech company's durable ARR is $15M versus $2M for the consumer company. The practical implication: healthtech startups should pursue multi-year contracts even at a discount. A 3-year contract at 85% of list price is worth more (in fundraising leverage and financial stability) than a monthly contract at full price.

Ehsan Jahandarpour

AI Growth Strategist & Fractional CMO

Forbes Top 20 Growth Hacker · TEDx Speaker · 716 Academic Citations · Ex-Microsoft · CMO at FirstWave (ASX:FCT) · Forbes Communications Council

Frequently Asked Questions

What is a good Annual Recurring Revenue (ARR) for HealthTech companies at Series B stage?

The median Annual Recurring Revenue (ARR) for HealthTech companies at the Series B stage is $3,599,161. Top‑quartile companies (75th percentile) significantly outperform this baseline. The most important factor is consistent improvement over time rather than hitting any single target number.

How does Annual Recurring Revenue (ARR) differ by company stage in HealthTech?

Annual Recurring Revenue (ARR) typically increases as HealthTech companies mature from seed through growth stage. Earlier‑stage companies should benchmark against stage‑appropriate peers rather than comparing themselves to mature companies.

How often should HealthTech companies measure Annual Recurring Revenue (ARR)?

HealthTech companies at the Series B stage should track Annual Recurring Revenue (ARR) monthly at minimum, weekly if possible. Set up automated dashboards and alerts for significant deviations from your baseline.

What factors most impact Annual Recurring Revenue (ARR) in the HealthTech sector?

In HealthTech, the primary factors impacting Annual Recurring Revenue (ARR) include product‑market fit maturity, competitive landscape intensity, customer segmentation strategy, pricing optimization, and operational efficiency. Series B‑stage companies should focus on the one or two highest‑leverage factors rather than trying to optimize everything simultaneously.

How does Annual Recurring Revenue (ARR) for HealthTech compare to cross‑industry benchmarks?

HealthTech Annual Recurring Revenue (ARR) benchmarks can differ significantly from cross‑industry averages due to factors specific to the HealthTech vertical including customer acquisition dynamics, competitive intensity, and typical deal sizes. Always compare against industry‑specific benchmarks rather than broad averages for meaningful insights.